Lemonex, mRNA-DegradaBALL vaccine LEM-mR203 clinical phase 1 trial IND submission
2023-02-14
疫苗临床1期信使RNA临床申请免疫疗法
SEOUL, South Korea I February 14, 2023 I Lemonex Inc., a biotechnology company pioneering messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system announced on the 14h of February that an Investigational New Drug (IND) application has been submitted to the Ministry of Food and Drug Safety (MFDS) for mRNA vaccine LEM-mR203 with its nano-drug delivery platform, DegradaBALL® on 20th of January.
This clinical trial is the first mRNA vaccine to which LemonexLemonex's proprietary drug delivery platform technology, DegradaBALL®, is applied. It is a booster shot clinical trial for Covid-19, and safety and reactogenicity will be evaluated in healthy adults.
Compared to existing antigen protein vaccines, mRNA vaccines can be developed quickly, making it easier to respond to pandemics, but drug delivery technology is essential for mRNA delivery in the body. However, LNP, a drug delivery technology applied to existing mRNA vaccines, has shown limitations such as safety issues including myocarditis, pericarditis, and anaphylaxis, the necessity of ultra-low-temperature cold chain and intellectual property disputes due to complex rights relations, which suggests a need for next-generation drug delivery technology. LemonexLemonex has secured intellectual property rights for the drug delivery technology of DegradaBALL®.
Dr. Dal-Hee Min, CTO of LemonexLemonex, Professor at Seoul National University, said, “LEM-mR203 is a safer and more efficient mRNA vaccine candidate by applying DegradaBALL® technology that can complement the limitations of LNP.” she said. “We already confirmed the safety of DegradaBALL in healthy people through the phase 1 clinical trial of LEM-S401 (a siRNA gene therapy product). By applying DegradaBALL with proven safety in healthy humans to mRNA vaccines, we will accelerate technology transfer and commercialization by securing the safety and proof-of-concept (PoC) of the mRNA-DegradaBALL® platform.”
Dr. Cheolhee Won, CEO of LemonexLemonex, said, “LEM-mR203 is a global first-in-class mRNA vaccine applied with DegradaBALL® drug delivery technology. In the case of LNP, mRNA fragmentation, and impurities may occur during the complex mRNA encapsulation process that must be performed immediately after mRNA synthesis in a dedicated facility. However, DegradaBALL® can be pre-produced and stored in stock and can increase mRNA stability. Through this platform technology, we plan to focus all of our core development capabilities on the ‘Pandemic Vaccine Development within 100 Days’ project.”
Meanwhile, LemonexLemonex is developing various new drug candidates based on the DegradaBALL® drug delivery platform. siRNA gene therapy LEM-S401: Completed administration and observation of the last subject in the phase 1 clinical trial, Dual-acting RNA immuno-oncology drug LEM-S403: Production of clinical samples for clinical entry after completion of the GLP-tox studies. In addition, Lemonex is strengthening its global network by signing an MOU with the International Vaccine Institute (IVI).
References
SOURCE: Lemonex
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。